Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 19/20 | 0.58 |
| ▸ | BCL2L11 | O43521 | 11/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17542338 | 1.00 | MCL1 (0.58) | MCL1BCL2L11CCND1KDM4C | |
| SCHEMBL17542341 | 1.00 | MCL1 (0.58) | MCL1BCL2L11CCND1KDM4C | |
| SCHEMBL23998005 | 0.97 | MCL1 (0.55) | MCL1BCL2L11CCND1 | |
| SCHEMBL19285255 | 0.94 | MCL1 (0.56) | MCL1BCL2L11KDM4C | |
| SCHEMBL29414598 | 0.89 | MCL1 (0.47) | MCL1BCL2L11CCND1 | |
| SCHEMBL17542372 | 0.89 | MCL1 (0.47) | MCL1BCL2L11CCND1 | |
| SCHEMBL17542374 | 0.89 | MCL1 (0.47) | MCL1BCL2L11CCND1 | |
| SCHEMBL20658783 | 0.87 | MCL1 (0.43) | MCL1KDM4C | |
| SCHEMBL29552834 | 0.87 | MCL1 (0.43) | MCL1KDM4C | |
| SCHEMBL17542276 | 0.86 | MCL1 (0.45) | MCL1BCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-11498928-B2 | Macrocyclic spiroethers as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-11-15 | — | — | US | disclosed |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11274105-B2 | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists | AMGEN INC. (US) | 2022-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | MCL1 1/4885BCL2L11 7/4885CCND1 1240/4885 |
| US-11498928-B2 | Macrocyclic spiroethers as Mcl-1 inhibitors | MCL1, BCL9, BCL9L | MCL1 1/4885BCL2L11 9/4885CCND1 52/4885 |
| US-11274105-B2 | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists | MCL1, BCL2A1, BCLAF1 | MCL1 1/4885BCL2L11 7/4885CCND1 1869/4885 |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | MCL1 1/4885BCL2L11 7/4885CCND1 1240/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | MCL1 1/4885BCL2L11 7/4885CCND1 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.